Related Experiment Video

Updated: Aug 29, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Disseminated intravascular coagulation: diagnosis, treatment and related pathophysiology

J F Tomera

    Drugs of Today (Barcelona, Spain : 1998)
    |January 27, 2004
    PubMed

    Insights

    This review evaluates disseminated intravascular coagulopathy (DIC), covering diagnosis, treatments, and biomarkers. It highlights promising new drugs and discusses disease associations for better understanding and management of DIC.

    Area of Science:

    • Hematology
    • Internal Medicine
    • Pathophysiology

    Background:

    • Disseminated intravascular coagulopathy (DIC) is a complex syndrome with significant morbidity and mortality.
    • Understanding the multifaceted nature of DIC, including its triggers and systemic effects, remains a clinical challenge.

    Purpose of the Study:

    • To provide a comprehensive, up-to-date evaluation of disseminated intravascular coagulopathy (DIC).
    • To explore current and emerging therapeutic strategies and diagnostic markers for DIC.
    • To elucidate the pathophysiological associations and risk factors contributing to DIC.

    Main Methods:

    • Systematic review of existing literature on DIC.
    • Analysis of clinical and differential diagnosis approaches.
    • Evaluation of pharmacological treatments, biological markers, and organ-specific effects.

    Main Results:

    • Optimal blood component therapy and indications for anticoagulants/antifibrinolytics in DIC are not definitively established.
    • Several novel therapeutic agents show promise for current and future DIC management.
    • New insights into disease occurrence and progression are offered through the examination of associated pathophysiologies.

    Conclusions:

    • Further research is needed to define optimal treatment regimens for DIC, including blood products and specific anticoagulants/antifibrinolytics.
    • Emerging pharmacological agents represent a significant advancement in the potential management of DIC.
    • Understanding the interplay between DIC and other pathophysiological conditions is crucial for improving patient outcomes.

    More Related Videos

    In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

    In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

    Published on: May 24, 2020

    Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)04:56

    Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

    Published on: August 4, 2023

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Venous Thrombosis I: Introduction01:30

    Venous Thrombosis I: Introduction

    Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
    Extrinsic and Intrinsic Pathways of Hemostasis01:20

    Extrinsic and Intrinsic Pathways of Hemostasis

    Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
    The Extrinsic Pathway
    The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
    Disorders of Hemostasis01:24

    Disorders of Hemostasis

    Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
    Thromboembolic Disorders
    Two factors primarily cause thromboembolic conditions.
    Coagulation01:09

    Coagulation

    The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
    During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...